Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,773 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunologic Disease Clear all
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 10, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

Descartes-25 in Relapsed/Refractory Multiple Myeloma

NCT05113342
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Descartes-25
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Shreveport, Louisiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

NCT00338494
View directory record Official record
Conditions
B-Cell Lymphoma
Interventions
Clofarabine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766
View directory record Official record
Conditions
Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 10, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT05706766
View directory record Official record
Conditions
Multiple Myeloma, Stem Cell Transplant Complications
Interventions
PARE, Waitlist Control Group
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Early Introduction and Sustained Ingestion (EISI) Using Two Educational Opportunities in Infants

NCT07321522
View directory record Official record
Conditions
Food Allergy
Interventions
Education and Opportunities on Early Introduction, Clinician Supervised Feeding of Known Allergenic Food
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Months to 11 Months
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

NCT01939951
View directory record Official record
Conditions
Mild to Moderate Persistent Asthma
Interventions
Activation Energy Serum
Dietary Supplement
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 10, 2026, 3:32 AM EDT
Not yet recruiting Not applicable Interventional

Food is Medicine in Pediatric Patients With Diabetes

NCT07535502
View directory record Official record
Conditions
Type I Diabetes, Pediatrics, Food Insecurity
Interventions
Community Servings, PedsQL Survey, Nutrition Counseling, SDOH Survey
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 10, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
ALPN-202
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Lafayette, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03226392
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Andalusia, Alabama • Birmingham, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Completed No phase listed Observational

Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants

NCT00246844
View directory record Official record
Conditions
Long-Functioning Pancreas Allografts, Pancreas Transplant
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 3:32 AM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Sep 10, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

NCT05892393
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI), Fludeoxyglucose F-18
Drug · Procedure · Other
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

NCT02994121
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
7 Years and older
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2047
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

NCT02374333
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma
Interventions
huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 24 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

NCT00238433
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care

NCT04199052
View directory record Official record
Conditions
HIV/AIDS
Interventions
LinkPositively
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 3:32 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

NCT07313852
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
Interventions
Blinatumomab Injection
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Self-Management in Young Adults With Type 1 Diabetes

NCT04975230
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep Self-Management
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 26 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 10, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

NCT02489500
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Melphalan, Neupogen, Stem Cell Collection, Stem cell infusion
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
RocketAP, USS Virginia
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 10, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03194867
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Cemiplimab REGN2810
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 10, 2026, 3:32 AM EDT